Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo.
about
Protective efficacy of a sulfated sialyl lipid (NMSO3) against human rotavirus-induced diarrhea in a mouse modelEmerging antiviral strategies to interfere with influenza virus entry.Effect of NMSO3 treatment in a murine model of human metapneumovirus infection.Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.An update on respiratory syncytial virus antiviral agents.The infectious march: the complex interaction between microbes and the immune system in asthma.Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.Orally active fusion inhibitor of respiratory syncytial virusIn search of a small-molecule inhibitor for respiratory syncytial virus.Emerging drugs for respiratory syncytial virus infection.Targeting RSV with vaccines and small molecule drugs.Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.Novel therapies for an old virus: treatment of RSV infections in the 21st Century.RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV GIntracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin.Mechanistic effect of NMSO3 on replication of human immunodeficiency virus.In vitro anti-influenza activity of a protein-enriched fraction from larvae of the housefly (Musca domestica).Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Development of liposomal nanoconstructs targeting P-selectin (CD62P)-expressing cells by using a sulfated derivative of sialic acid.
P2860
Q28345176-3D6A211C-048F-4705-9D77-9138DF5270F3Q30432421-60038BC8-B06A-4203-B774-FC552D480C9AQ33567504-7C58713A-266B-426D-88F2-07F80FCD314CQ33776507-6DEE33EB-31D1-4A41-B209-C6078158F2C6Q34141078-D5E68699-03BE-4F52-80CD-6C17E0CE14BBQ34356430-DC292F8D-2DD7-496C-A0FF-430EF315A230Q35124942-2C42F22F-B00F-406C-A981-E31EE99CF1DBQ35547902-3974E50C-B4AB-4EC5-917E-1B83EEA72463Q35917503-02C5FAC8-1F2C-43FF-A023-653838236D58Q37250650-9E7C6950-8DE7-4554-85B6-048DEE6586E2Q37328584-F11CEF23-215B-41A5-95A6-EFAD8AC7BFA8Q37596447-EFB7BF02-C578-4A22-9E68-FDA5DEDCB98FQ37626071-61CF17EE-C3E9-43E1-BD0F-2B570BE25865Q37730065-5DBA568F-5608-46F8-80E1-BC3927112FA1Q39323887-E1B7BC15-4AEA-499B-9C08-02B99468D63AQ40622213-F5305788-98C9-48DB-A48A-93275C2115ABQ42287407-9D8B1797-900B-4B3E-A62A-191AC671F9D3Q47549703-F042CA93-D652-4B3E-8D52-9AA5C2209F17Q51748923-16E87B17-CFFB-4EF7-83D9-578B8A944796
P2860
Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antiviral activity of NMSO3 ag ...... nfection in vitro and in vivo.
@ast
Antiviral activity of NMSO3 ag ...... nfection in vitro and in vivo.
@en
type
label
Antiviral activity of NMSO3 ag ...... nfection in vitro and in vivo.
@ast
Antiviral activity of NMSO3 ag ...... nfection in vitro and in vivo.
@en
prefLabel
Antiviral activity of NMSO3 ag ...... nfection in vitro and in vivo.
@ast
Antiviral activity of NMSO3 ag ...... nfection in vitro and in vivo.
@en
P2093
P1433
P1476
Antiviral activity of NMSO3 ag ...... nfection in vitro and in vivo.
@en
P2093
Takahashi K
P356
10.1016/S0166-3542(00)00091-7
P577
2000-07-01T00:00:00Z